Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee

NCT02003365 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteoarthritis of the Knee

Interventions

DRUG: FX006 10 mg
DRUG: FX006 40 mg
DRUG: TCA IR 40 mg

Sponsor

Pacira Pharmaceuticals, Inc